However, when they are re-modulated by TLR7/TLR9 ligands, their tolerogenic phenotype gets shifted to activated form and mediate effective anti-tumor immunity through the activation of myeloid DCs, NK cells, and CD8+ T cells in solid tumors (69, 70). The gene discussed is CD8A; the disease is neoplasm.